ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements
Jenburkt Pharmaceuticals clarified its shares are permitted to trade on NSE without a listing application. The shares remain listed on BSE under the Permitted to Trade category.
Mr. Vinay Bhatt, Senior Vice President- International Business, has resigned from Jenburkt Pharmaceuticals Limited effective September 18, 2026, due to personal reasons.
Jenburkt Pharmaceuticals held its 41st Annual General Meeting on 4th September, 2026, to discuss financial statements, dividend declaration, and director appointments.
Jenburkt Pharmaceuticals elevated Shri Prem Ashish Bhuta to Associate Vice President – Strategic Initiatives. He is now classified as Senior Management Personnel effective September 4, 2026.
Jenburkt Pharmaceuticals Ltd reported revenue from operations of ₹35.5 Cr (+0.0% YoY) and net profit of ₹5.9 Cr (-24.4% YoY) for Q1 FY27.
Jenburkt Pharmaceuticals Limited has scheduled its 41st Annual General Meeting for September 4, 2026, through video conferencing. Shareholders will vote on financial adoption, dividend declaration, and director appointments.
Jenburkt Pharmaceuticals Ltd reported revenue from operations of ₹168.7 Cr (+11.2% YoY) and net profit of ₹34.7 Cr (+8.1% YoY) for Q4 FY26.
Jenburkt Pharmaceuticals scheduled a board meeting for August 6, 2026, to consider the company's standalone unaudited financial results for the quarter ended June 30, 2026.
Jenburkt Pharmaceuticals approved shifting its registered office within Mumbai effective July 21, 2026. Contact details and ROC jurisdiction remain unchanged.
Jenburkt Pharmaceuticals Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. Issued by Nilesh Shah & Associates, the report confirms general compliance with SEBI regulations, though it notes minor clarifications were previously required by the BSE regarding financial result filings.
Jenburkt Pharmaceuticals has fixed August 28, 2026, as the record date for its FY 2025-26 dividend. Payment is scheduled within 30 days of the AGM on September 4, 2026. The same date serves as the cut-off for e-voting eligibility.
Jenburkt Pharmaceuticals Ltd reported revenue from operations of ₹44.6 Cr (+8.8% YoY) and net profit of ₹10.8 Cr (+27.1% YoY) for Q4 FY26.
Jenburkt Pharmaceuticals Limited reported its audited financial results for FY 2025-26, alongside a recommended dividend of ₹20.70 (207%) per equity share. The Board also approved the re-appointment of Shri Dilip H. Bhuta as Whole time Director and CFO for a five-year term starting April 2027.
Jenburkt Pharmaceuticals Ltd has scheduled a board meeting on May 05, 2026. The board will review audited financial results for the quarter and year ended March 31, 2026, and consider a dividend recommendation.
Jenburkt Pharmaceuticals Limited confirmed it does not meet the 'large corporate' criteria for the financial year ended March 31, 2026. This disclosure complies with SEBI's framework for debt-raising norms. The company is not currently subject to the mandatory incremental borrowing requirements applicable to large corporates.
Jenburkt Pharmaceuticals submitted a compliance certificate for the quarter ended March 31, 2026, confirming that securities received for dematerialization were processed, mutilated, and cancelled by its Registrar and Transfer Agent, Bigshare Services Pvt. Ltd. This is a routine regulatory disclosure with no material financial impact.